BioSpace News Archive

- Expedited Access to OXLUMO Aims to Support Children and Adults Living with PH1 who Face Inevitable Disease Progression and Irreversible Kidney Damage in the Absence of New Treatment Options - - New Value-Based Agreement Framework Includes an Innovative Patient Need Adjustment that Offers Payers Increased Cost Predictability Across the Entire Spectrum of PH1 Patient Ages, from Infant to Adult -

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma First immunotherapy to be approved for a gastroesophageal cancer in the European Union Approval based on Phase 3 ATTRACTION-3 trial showing statistically significant and clinically meaningful improvement in overall survival compared to chemotherapy

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that following a late-breaking oral presentation of its Phase II Namodenoson study in the treatment of NAFLD/NASH delivered at the American Association for the Study of Liver Diseases (AASLD) conference, the

– First RNAi Therapeutic Approved in U.S. for Use in Both Children and Adults, and Third RNAi Medicine to Receive FDA Approval in Less than Three Years – – Approval Based on Results from Both ILLUMINATE-A and ILLUMINATE-B Phase 3 Studies, Demonstrating Clinically Significant Reductions in Urinary Oxalate and Encouraging Safety and Tolerability Across a Broad Spectrum of Patient Ages –

Implements New Corporate Strategy to Focus on Precision Therapeutics for the Treatment of Cancer Strengthens Pipeline by Acquiring a Proprietary Portfolio of Novel Adenosine Immuno-Modulator Compounds Increased Cash Runway by Securing $500,000 of Gross Proceeds From an Existing Institutional Investor in October 2020

Lantern Pharma announced that Panna Sharma, CEO and President, will participate in the following investor events in December:

MindMed, a leading psychedelic medicine biotech company, is establishing a digital medicine division known as Albert.

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it has achieved Gold status in the American Heart Association’s 2020 Workpl

AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the Piper Sandler 32 nd Annual Virtual Healthcare Conference on December 1, 2020. The presentations will be available for registered attendees via the Piper Sandler conference site from November 23 to December 3 and will al

Curtis Mathes Corporation (OTC: TLED) subsidiary, Curtis Mathes Therapeutics, Inc. (CMTI) has received 60+ red light therapy (RLT) modules for initial photonics testing and product fabrication. CMTI’s RLT units will feature a novel spectrum of light that has been shown in the scientific literature to greatly accelerate recovery fr